Mulder N H, Dolsma W V, Mulder P O, De Vries E G, Willemse P H, Sleijfer D T, Hospers G A, Van der Graaf W T
Department of Medical oncology, University Hospital Groningen, The Netherlands.
Anticancer Res. 1995 Jul-Aug;15(4):1565-8.
Twenty-nine patients with metastatic or T4 breast cancer who were in pathologically proven complete remission after induction chemotherapy, received intensification chemotherapy with autologous bone marrow support. Twelve patients had T4 breast cancer, 17 had metastatic disease. The median age was 42 years (27-52). Intensification consisted of cyclophosphamide 7 g/m2 i.v. and etoposide 1.5 g/m2 i.v. in 24 patients, or thiotepa 800 mg/m2 i.v. and mitoxantrone 50-75 mg/m2 i.v. in 5 patients. The median observation is 7 years. Median survival is 36 months. Ten year relapse-free survival is 20%. For patients with metastatic disease median survival is 34 months, time to relapse 18 months; two patients (12%) have survived disease-free for more than 6 years. The patients with T4 cancer have a median survival of 80 months and a median time to relapse of 53 months; four patients (33%) have survived more than 5 years disease-free.
29例转移性或T4期乳腺癌患者在诱导化疗后经病理证实达到完全缓解，接受了自体骨髓支持下的强化化疗。其中12例为T4期乳腺癌患者，17例有转移性疾病。中位年龄为42岁（27 - 52岁）。24例患者的强化治疗方案为静脉注射环磷酰胺7 g/m²和依托泊苷1.5 g/m²，5例患者的强化治疗方案为静脉注射噻替派800 mg/m²和米托蒽醌50 - 75 mg/m²。中位观察期为7年。中位生存期为36个月。10年无复发生存率为20%。转移性疾病患者的中位生存期为34个月，复发时间为18个月；2例患者（12%）无病生存超过6年。T4期癌症患者的中位生存期为80个月，中位复发时间为53个月；4例患者（33%）无病生存超过5年。
